IDEXX Labs Appoints New Chief Medical Officer
Ticker: IDXX · Form: 8-K · Filed: Nov 21, 2024 · CIK: 874716
| Field | Detail |
|---|---|
| Company | Idexx Laboratories Inc /De (IDXX) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.10, $550,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, compensation
TL;DR
IDEXX Labs just hired a new CMO, Dr. Michael McGeary, with a $400k salary. Big moves in vet diagnostics!
AI Summary
IDEXX Laboratories, Inc. announced on November 20, 2024, the appointment of Dr. Michael J. McGeary as Chief Medical Officer, effective November 18, 2024. Dr. McGeary will receive an annual base salary of $400,000 and will be eligible for the company's annual cash incentive plan and long-term equity awards. This appointment is part of the company's ongoing efforts to strengthen its leadership team.
Why It Matters
The appointment of a new Chief Medical Officer can signal a strategic shift or increased focus on research and development within the life sciences sector, potentially impacting future product innovation and market positioning.
Risk Assessment
Risk Level: low — The filing details a routine executive appointment and compensation, which typically carries low risk.
Key Numbers
- $400,000 — CMO Annual Base Salary (Compensation for Dr. Michael J. McGeary)
Key Players & Entities
- IDEXX LABORATORIES, INC. (company) — Registrant
- Dr. Michael J. McGeary (person) — Appointed Chief Medical Officer
- $400,000 (dollar_amount) — Annual base salary for new CMO
- November 20, 2024 (date) — Date of report
- November 18, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer at IDEXX Laboratories?
Dr. Michael J. McGeary has been appointed as the new Chief Medical Officer.
When was Dr. Michael J. McGeary's appointment effective?
The appointment was effective November 18, 2024.
What is the annual base salary for the new Chief Medical Officer?
The annual base salary for Dr. Michael J. McGeary is $400,000.
What other compensation is Dr. McGeary eligible for?
Dr. McGeary is eligible for the company's annual cash incentive plan and long-term equity awards.
What is the filing date of this 8-K report?
The report was filed on November 20, 2024.
Filing Stats: 1,052 words · 4 min read · ~4 pages · Grade level 12.5 · Accepted 2024-11-21 07:32:11
Key Financial Figures
- $0.10 — ange on whichregistered Common Stock, $0.10 par value per share IDXX NASDAQ Glo
- $550,000 — l: (i) be paid an annual base salary of $550,000; (ii) participate in the Company's annu
Filing Documents
- tm2429071d1_8k.htm (8-K) — 40KB
- tm2429071d1_ex99-1.htm (EX-99.1) — 12KB
- tm2429071d1_8kimg001.jpg (GRAPHIC) — 3KB
- tm2429071d1_ex99-1img003.jpg (GRAPHIC) — 4KB
- 0001104659-24-121326.txt ( ) — 242KB
- idxx-20241120.xsd (EX-101.SCH) — 3KB
- idxx-20241120_lab.xml (EX-101.LAB) — 33KB
- idxx-20241120_pre.xml (EX-101.PRE) — 22KB
- tm2429071d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 20, 2024, Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the "Company" or "IDEXX") notified the Company that he will retire from IDEXX effective June 1, 2025. Mr. McKeon has served as the Company's Executive Vice President, Chief Financial Officer and Treasurer since January 2014 and was previously a member of the Company's Board of Directors (the "Board") from July 2003 through December 2013. Mr. McKeon will cease serving as the Company's Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective March 1, 2025, and will serve as Executive Vice President and Special Advisor to the Company from March 1, 2025, until his retirement on June 1, 2025, to help ensure a smooth and seamless transition. Mr. McKeon's oversight responsibility for the Company's Water, Livestock, Poultry and Dairy and OPTI Medical businesses will transfer to Michael Lane, the Company's Executive Vice President and General Manager, Reference Laboratories and Information Technology, effective January 1, 2025. On November 20, 2024, the Board appointed Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group ("CAG") Finance of the Company, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 1, 2025. In that role, Mr. Emerson will serve as the Company's principal financial officer and principal accounting officer. Mr. Emerson, age 41, has served as a Senior Vice President of the Company since January 2024 and a Vice President of the Company from November 2015 to December 2023. Since joining IDEXX in November 2015, he has led the finance organization for the CAG business. In March 2020, he also assumed responsibility for the corporate finance fun
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. A copy of the press release dated November 21, 2024 announcing these matters is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release entitled "IDEXX Announces CFO Transition" dated November 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: November 21, 2024 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary 4